Back to Archived News
Patent Partner Todd Lorenz Joins King & Spalding’s Intellectual Property Group
Thursday, July 24, 2008
San Francisco, CA -- King & Spalding, a leading international law firm, announced today that Todd A. Lorenz, a patent lawyer with significant experience in the biotechnology and pharmaceutical fields, has joined the firm as a partner in its intellectual property practice group. Lorenz will be resident in the firm's San Francisco office.
"The addition of Todd reflects our commitment to strategically enhance our Life Sciences practice with top-tier lateral hires," said Courtland L. Reichman, head of the firm's intellectual property practice group.
Lorenz joins King & Spalding from Dorsey & Whitney LLP where he was a partner and served as co-chair of Dorsey's Life Sciences practice. He has over fifteen years of experience in the acquisition, licensing and litigation of biotech patents, and represents a number of emerging and public biotech companies, leading universities, and venture firms in the fields of immunology, oncology, neurology and molecular biology. He has worked with leaders in large molecule and cell-based therapeutics, including antibodies, peptides, stem cells, gene therapy, siRNA, antisense, vaccines and adjuvants; clinical and research diagnostics, including novel targets and analytical platforms; and fundamental molecular biology reagents and procedures.
Lorenz earned a B.S. from Rensselaer Polytechnic Institute, and a J.D. from Boston University School of Law.
King & Spalding has one of the broadest and deepest benches of lawyers, scientists and consultants in the United States specializing in the representation of pharmaceutical, biotechnology and medical technology companies. More than 125 lawyers and professionals devote all or a substantial portion of their practices to clients in these industries, with specialized experience at every stage of the product life cycle -- from emerging growth company counseling on intellectual property and clinical trials, through licensing and finance, to FDA approval, manufacturing, and marketing, and post-approval regulatory, transactional, and litigation matters. Since the opening of its San Francisco and Silicon Valley offices earlier this year, the firm has added 24 lawyers and professionals in California who focus on advising pharmaceutical, biotech, and medical device companies.
King & Spalding's intellectual property practice group consists of more than 100 lawyers and patent agents in the firm's offices in Atlanta, Charlotte, Houston, New York, San Francisco, Silicon Valley, and Washington, D.C. The group houses a "full service" intellectual property practice, including significant capabilities in patent litigation and prosecution, trademark litigation and prosecution, and false advertising.
About King & Spalding
King & Spalding is an international law firm with more than 800 lawyers in Abu Dhabi, Atlanta, Austin, Charlotte, Dubai, Frankfurt, Houston, London, New York, Riyadh (affiliated office), San Francisco, Silicon Valley and Washington, D.C. The firm represents half of the Fortune 100 and in a Corporate Counsel survey in September 2007 was among the top firms representing Fortune 250 companies. For additional information, visit www.kslaw.com.
Back to Archived News